Molbio Diagnostics, a point-of-care (POC) diagnostics company, and UE LifeSciences, a Philadelphia-based health technology innovator focused on early cancer detection, have announced an exclusive collaboration to expand access to early breast cancer detection in more than 50 countries across the developing world.
As part of this collaboration, Molbio will distribute UE LifeSciences’ iBreastExam, a radiation-free, painless, and US Food and Drug Administration (FDA)-cleared screening device, across India, Africa, the Middle East, CIS countries, the Philippines, Indonesia, and Vietnam. The aim is to address the challenge of late detection, which remains a leading cause of preventable breast cancer mortality.
Molbio Diagnostics will use its global distribution network and experience in scaling healthcare technologies to promote, market, sell, and distribute iBreastExam to public and private healthcare providers in these regions.
The iBreastExam is a POC, ultraportable, battery-operated device designed to enable screening in primary healthcare centres and large-scale public health campaigns. It can detect breast lumps in minutes without pain, radiation, or complex infrastructure. Using advanced sensor technology, the device automates and enhances physical breast examination without requiring user interpretation.
Its portability and ease of use allow early detection directly within communities, helping overcome barriers to mammogram access in low-resource settings. The device also features secure cloud storage to support patient follow-up, enabling timely diagnosis and care.
Mihir Shah, Founder and CEO of UE LifeSciences, said, “Our collaboration with Molbio Diagnostics is an important step towards improving access to early breast health screening, particularly in areas where access to screening remains a challenge.”
He added, “Molbio’s experienced team and market reach can help amplify our mission to transform women’s health and save lives through accessible and innovative early detection.”